Market research
4593.TSE Healios K.K
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 41B
- P/E ratio
- 290.38
- Analyst target
- 794.8333
- Dividend yield
- Not available
- Beta
- 1.35
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- JP3835100003
- Market cap
- 41B
- P/E ratio
- 290.38
- Analyst target
- 794.8333
- Dividend yield
- Not available
- Beta
- 1.35
About
About Healios K.K
Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration and AKT-01/HLCN061, which is in pre-clinical trial for the treatment of Mesothelioma, Lung cancer, Hepatocellular carcinoma and Gastric cancer(solid tumors). It also develops somatic stem cell and induced pluripotent stem cell regenerative medicines. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Chiyoda, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4593.TSE discussion.
5 years, 6 months ago
Healios K.K is currently in a long term downtrend where the price is trading 6.7% below its 200 day moving average.
From a valuation standpoint, the stock is 4572.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 3294.7.
Healios K.K's total revenue sank by 14.3% to $6M since the same quarter in the previous year.
Its net income has dropped by 18.4% to $-1B since the same quarter in the previous year.
Finally, its free cash flow fell by 22.0% to $-1B since the same quarter in the previous year.
Based on the above factors, Healios K.K gets an overall score of 0/5.